HomeInsightsMarket Capitalization

Market Capitalization of Marksans Pharma Ltd

Market Capitalization of Marksans Pharma Ltd

stocks purchased

₹ 3.2 Cr

Volume Transacted

(Nov 22, 2024)

stocks purchased

104.3 K

Stocks Traded

(Nov 22, 2024)

Last Updated on: Nov 23, 2024

Image

Marksans Pharma Ltd

NSE: MARKSANS

Market Cap

₹ 13982.37 crore

Last updated on: Nov 22, 2024

Key Highlights

  • The Market Cap of Marksans Pharma Ltd is ₹ 13982 crore as of 22 Nov 24 .
  • The Market Cap of Marksans Pharma Ltd changed from ₹ 1017 crore on March 2019 to ₹ 6867 crore on March 2024 . This represents a CAGR of 37.48% over 6 years.
  • The Latest Trading Price of Marksans Pharma Ltd is ₹ 308.55 as of 22 Nov 15:30 .
  • The dividend payouts of Marksans Pharma Ltd changed from ₹ 0.05 to ₹ 0.6 over 6 quarters. This represents a CAGR of 424.15% .

Historical Market Cap of Marksans Pharma Ltd

No data available

* All values are in crore

Company Fundamentals for Marksans Pharma Ltd

No data available

Image

Marksans Pharma Ltd

NSE: MARKSANS

Share Price

₹ 308.55

-0.45 (-0.15%)

stock direction

Last updated on: Nov 22, 2024

Market Price of Marksans Pharma Ltd

1M

1Y

3Y

5Y

Monitoring Marksans Pharma Ltd share price can help you stay informed about potential market shifts and opportunities. *All values are in Rupees.

Last Ten Days Market Price

Date
leftPrice (₹)right
22 Nov 2024308.55
21 Nov 2024309
19 Nov 2024305.85
18 Nov 2024309.3
14 Nov 2024307.35
13 Nov 2024305.55
12 Nov 2024300.35
11 Nov 2024289
08 Nov 2024298.6
07 Nov 2024301.35

SWOT Analysis Of Marksans Pharma Ltd

Strength

2

S

Weakness

1

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Marksans Pharma Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

Asset Value vs Market Value of Marksans Pharma Ltd

Market Value

0

Asset Value

0

* All values are in Rupees

Competitive Comparison of Market Cap

Key Valuation Metric of Marksans Pharma Ltd

No data available

No data available

Historical P/E Ratio of Marksans Pharma Ltd

No data available

* All values are in %

Historical Revenue of Marksans Pharma Ltd

No data available

* All values are in crore

Historical EBITDA of Marksans Pharma Ltd

No data available

* All values are in crore

Historical Net Profit of Marksans Pharma Ltd

No data available

* All values are in crore

Historical Dividend Payouts of Marksans Pharma Ltd

No data available

* All values are in

About Marksans Pharma Ltd

  • Marksans Pharma Limited was formerly incorporated as Tasc Pharmaceuticals Limited in April, 1982.
  • Pursuant to the Scheme of Amalgamation, name of the Company was changed from Tasc Pharmaceuticals Limited to Marksans Pharma Limited with effect from 10th October, 2005.
  • The Company primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulation.
  • The Company's research and development facilities are located in Verna, Goa and R & D center in Navi Mumbai. In 2004-05, the Company amalgamated with M/s.
  • Marksans Pharma Limited (formerly M/s.

Marksans Pharma Ltd News Hub

News

Marksans Pharma receives USFDA approval for Loratadine Tablets

Marksans Pharma announced the final approval of the Company's Abbreviated New Drug Applica...

Read more

22 Nov 202412:47

News

Marksans Pharma gains after receiving final nod for Loratadine Tablets from USFDA

The said drugs are indicated for the treatment of allergic rhinitis caused by pollen and u...

Read more

22 Nov 202413:23

News

Marksans Pharma gains after Q2 PAT rises 16% YoY to Rs 97 cr

The firm stated that growth was witnessed across all key markets, led by US and followed b...

Read more

12 Nov 202413:22

News

Marksans Pharma to declare Quarterly Result

Marksans Pharma will hold a meeting of the Board of Directors of the Company on 12 Novembe...

Read more

23 Oct 202417:41

News

Marksans Pharma announces receipt of UKMHRA approval for Fluoxetine capsules

Marksans Pharma'announced that its wholly owned subsidiary Relonchem has received Marketin...

Read more

21 Aug 202420:00

News

Marksans Pharma's Verna unit successfully completes USFDA inspection

Marksans Pharma announced that he USFDA has issued an Establishment Inspection Report (EIR...

Read more

20 Aug 202414:37

Product Composition

Document

Annual Reports

N/A

dropdown
download

Credit Ratings

N/A

dropdown
download

Concalls

Data not available

FAQs for Marksans Pharma Ltd Market Cap

What is the market cap of Marksans Pharma Ltd?

As of November 23, 2024, Marksans Pharma Ltd has a market capitalization of ₹13982.37, however, this figure is subject to change due to fluctuations in its stock price and market conditions.

What factors influence Marksans Pharma Ltd's market capitalization?

Marksans Pharma Ltd's market capitalization is influenced by factors such as its financial performance, and the company’s ability to innovate and adapt to market trends. Moreover, macroeconomic factors like economic conditions, currency fluctuations, and global automotive industry trends also affect its market capitalization.

Can market capitalization be used to predict future stock performance of Marksans Pharma Ltd?

Market capitalization alone is not a reliable predictor of future stock performance, as it reflects the current value of a company's equity rather than its future potential. To forecast %s's future stock performance, investors should consider additional factors such as financial health, growth prospects, industry trends, and broader economic conditions.

How often does Marksans Pharma Ltd's market capitalization change?

Marksans Pharma Ltd's market capitalization can change frequently, within a single trading day, due to fluctuations in stock price. These changes are influenced by market conditions, investor sentiment, company performance, and broader economic factors. Therefore, tracking its market capitalization requires continuous monitoring of stock price movements and related financial news.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
50yearstrust

Unlimited trading at just

Rs. 399

Rs. 199*